An interim analysis of data from Phase III trials published in the Lancet today shows that the ChAdOx1 nCoV-2019 vaccine, developed by University of Oxford and AstraZeneca, administered in two doses, was highly effective. Guy’s and St Thomas’ NHS Foundation Trust is a participating centre in this trial.
The vaccine was 90% effective if administered at a half dose and then at a full dose, or 62% effective if administered in two full doses. The data also showed lower rates of asymptomatic infection in the people who had received the half dose followed by a full dose regimen, which suggests that the vaccine could help to prevent transmission of the virus. Additionally, there were no hospitalised or severe cases of COVID-19 in anyone who received the vaccine.
The research to date has been made possible thanks to the 24,000 volunteers who took part in the trial, and the hard work of the talented teams who delivered the research around the world.
Dr Anna Goodman, consultant in infectious diseases, who is the Principal Investigator for the trial at Guy’s and St Thomas’, said: “Over 400 research, clinical and non-clinical staff supported the delivery of the trial at Guy’s and St Thomas’. We are extremely proud and grateful for every single contribution. It is only because of the selfless commitment of the trial participants and dedication of teams just like ours around the world that this work to help halt the progress of the pandemic has been possible. A sincere thank you to each and every one of you.”
Those who supported the trial at Guy’s and St Thomas’ include:
All of the 492 participants in the trial at Guy’s and St Thomas’.
R&D governance team
R&D communications team
Guy’s and St Thomas’ communications team
The Clinical Research Facility team
Nursing and midwife staffing tactical
Rare Disease Centre team
COVID-19 research team
COVID-19 research reception team
The XP support group (https://xpsupportgroup.org.uk/)
Guy’s and St Thomas’ Charity (www.gsttcharity.org.uk)
Joshua Au Yeung
Sara Jane Lyons